{"id":"W1554484942","doi":"10.1158/1538-7445.am2015-ct136","title":"Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; KRAS; Cetuximab; Internal medicine; Tolerability; Colorectal cancer; Oncology; Adverse effect; Cancer; Hypophosphatemia; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001313361,0.001242591,0.001454662,0.0003444733,0.0003360994,0.0006925962,0.0006114175,0.000652291,0.003026655],"category_scores_gemma":[0.0008857863,0.000400072,0.0009001769,0.0003866254,0.0005412318,0.0004080219,0.0003514905,0.001669003,0.0005811733],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001130753,"about_ca_system_score_gemma":0.00177379,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001312713,"about_ca_topic_score_gemma":0.00249897,"domain_scores_codex":[0.9994506,0.000259666,0.00003869025,0.00009786072,0.00008152393,0.0000715967],"domain_scores_gemma":[0.9993758,0.0000687543,0.0001204091,0.0000643979,0.00007497,0.0002956766],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5960067,0.02361314,0.02313124,0.0008499361,0.002414465,0.0003909862,0.0002383098,0.003721311,0.2507416,0.0001952675,0.002674847,0.09602216],"study_design_scores_gemma":[0.1641045,0.7280672,0.05817592,0.00004290424,0.001702246,0.0009449563,0.00005864594,0.001579648,0.03923982,0.00008256912,0.005952783,0.00004884581],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948161,0.001307095,0.0005476301,0.0001428885,0.00003612312,0.001038626,0.0009626743,0.0000556605,0.00109318],"genre_scores_gemma":[0.9908755,0.0007186445,0.001472612,0.0001917158,0.00004952362,0.0007508185,0.003763996,0.00001812,0.002159146],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003026655,"threshold_uncertainty_score":0.01012522,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07167755327505136,"score_gpt":0.3857461648551156,"score_spread":0.3140686115800642,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}